PMID- 35578191
OWN - NLM
STAT- MEDLINE
DCOM- 20220518
LR  - 20221207
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 22
IP  - 1
DP  - 2022 May 17
TI  - Quality of care in type 2 diabetes in Iran; a cross-sectional study using 
      patient-level data.
PG  - 133
LID - 10.1186/s12902-022-01034-2 [doi]
LID - 133
AB  - BACKGROUND: Appropriate service delivery, access to high quality of cares and 
      optimal management of type 2 diabetes mellitus (T2DM) can decrease the risk of 
      micro and macro vascular complications and mortality. Therefore, monitoring the 
      quality of diabetes care, including keeping glycemic levels at an optimal level, 
      is crucial. The aim of this study was to evaluate processes and outcome-related 
      quality of care indicators, in T2DM using retrospective patient-level data from 
      2013 to 2017 in 15 Tertiary Diabetes Care Centers in Iran. METHOD: A 
      retrospective observational study was conducted among 1985 T2DM patients at 
      public, semipublic and private diabetes centers. Annual tests for HbA1c, serum 
      lipid (LDL), and screening for nephropathy were used to evaluate process-related 
      indicators; and intermediate biomedical markers including HbA1c, blood pressure 
      (BP), and LDL cholesterol, were used to assess outcome-related indicators. 
      RESULTS: Data were extracted from 15 diabetes centers in five provinces in Iran. 
      62.7% of the patients were female, and the mean duration of diabetes in the 
      patients was 14.7 years. Evaluation of process-related indicators showed that 
      only 9% of patients took the HbA1c test. The percentage of the patients without 
      annual low-density lipoprotein (LDL) test decreased from 13% in 2013 to 7% in 
      2017. The results of achieving to all indicators concurrently (ABC care) showed 
      that less than 2% of the patients met the criteria of optimal process-related 
      quality indicators. The mean percentage of the patients with HbA1c under 7%, 
      blood pressure (BP) less than 130/80 mmHg, and LDL less than 100 mg(/dl) in the 
      selected provinces were 32.4, 55, and 71 respectively. However, the average of 
      total achievement in ABC goals was 14.2%. CONCLUSION: Our findings showed that 
      the management of T2DM in all selected provinces was far from the optimal control 
      in both processes and outcome-related indicators and therefore needs serious 
      consideration and improvement.
CI  - (c) 2022. The Author(s).
FAU - Davari, Majid
AU  - Davari M
AD  - Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of 
      Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Bayazidi, Yahya
AU  - Bayazidi Y
AD  - Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of 
      Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. 
      ybayazidi@gmail.com.
FAU - Kebriaeezadeh, Abbas
AU  - Kebriaeezadeh A
AD  - Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of 
      Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Esteghamati, Alireza
AU  - Esteghamati A
AD  - Endocrinology and Metabolism Research Center, Vali-Asr Hospital, School of 
      Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Bandarian, Fatemeh
AU  - Bandarian F
AD  - Endocrinology and Metabolism Research Center, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Kashi, Zahra
AU  - Kashi Z
AD  - Diabetes Research Center, Mazandaran University of Medical Sciences, Mazandaran, 
      Iran.
FAU - Bahar, Adele
AU  - Bahar A
AD  - Diabetes Research Center, Mazandaran University of Medical Sciences, Mazandaran, 
      Iran.
FAU - Yousefi, Sepideh
AU  - Yousefi S
AD  - Pharm-D, Faculty of Pharmacy and Pharmaceutical Science, Islamic Azad University 
      of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220517
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - Blood Pressure
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/epidemiology/therapy
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Iran/epidemiology
MH  - Male
MH  - Retrospective Studies
PMC - PMC9112515
OTO - NOTNLM
OT  - ABC Care
OT  - HbA1c
OT  - Iran
OT  - Optimal Control
OT  - Quality of Care
OT  - Type 2 Diabetes
COIS- The authors declare that they have no competing interests.
EDAT- 2022/05/17 06:00
MHDA- 2022/05/19 06:00
PMCR- 2022/05/17
CRDT- 2022/05/16 23:44
PHST- 2021/09/19 00:00 [received]
PHST- 2022/04/27 00:00 [accepted]
PHST- 2022/05/16 23:44 [entrez]
PHST- 2022/05/17 06:00 [pubmed]
PHST- 2022/05/19 06:00 [medline]
PHST- 2022/05/17 00:00 [pmc-release]
AID - 10.1186/s12902-022-01034-2 [pii]
AID - 1034 [pii]
AID - 10.1186/s12902-022-01034-2 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2022 May 17;22(1):133. doi: 10.1186/s12902-022-01034-2.